" class="no-js "lang="en-US"> Pedro Malha - Medtech Alert
Saturday, May 03, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Pedro Malha

Pedro Malha

About Pedro Malha

Healthcare senior executive with +20 years of global Medical Device and Pharmaceutical experience in Fortune 500 companies. Proven track record in driving share and building high performance teams. Core competencies: Global P&L Management • Turnarounds • Strategic Planning • M&A and Integration • Global Manufacturing Operations • Global Marketing and Sales • Global R&D • Global Product Launches • Change Management • Leadership Development

Related Story

Equipment

 FDA Approves Abbott's New Spinal Cord Stimulation Device; Provides Tailored Relief to Multiple Pain Areas and Adds More Treatment Options for Evolving Pain Conditions | Pharmtech Focus

FDA Approves Abbott's New Spinal Cord Stimulation Device; Provides Tailored Relief to Multiple Pain Areas and Adds More Treatment Options for Evolving Pain Conditions

August 24 2022

Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved its […]

Health Apps

 Abbott Strengthens Its Connected Care Technologies with Latest Neurosphere™ Mypath™ Digital Health App | Pharmtech Focus

Abbott Strengthens Its Connected Care Technologies with Latest Neurosphere™ Mypath™ Digital Health App

April 26 2022

Abbott (NYSE: ABT) today announced that it has launched an upgraded version of its NeuroSphere™ […]